Matthew R. Zibelman, MD, discusses treatment options in muscle-invasive, perioperative, and metastatic bladder cancer.

Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

Despite concerns over cabozantinib's patent expiry, Exelixis projects robust future revenues, with lead pipeline candidate ...

Investment analysts at TD Cowen began coverage on shares of CG Oncology (NASDAQ:CGON – Get Free Report) in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The ...